Application of Qingjin Qi-tonifying composition in preparation of medicine for treating or preventing pharyngitis

The Qingjin Yiqi composition addresses the problems of antibiotic resistance and low mucosal immune function in existing technologies by improving immune cell subsets and reducing inflammatory factor levels, providing a safe and effective treatment for acute pharyngitis.

CN118903337APending Publication Date: 2024-11-08TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411247419.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Current technologies for treating acute pharyngitis suffer from problems such as antibiotic resistance and dysbiosis of the gut microbiota, and there is a lack of safe and effective drugs to suppress the inflammatory response and improve mucosal immune function.

Method used

The Qingjin Yiqi Composition, containing ginseng, ophiopogon japonicus, schisandra chinensis, poria cocos, pinellia ternata, coix seed, scrophularia ningpoensis, atractylodes lancea, tangerine peel, licorice, bupleurum chinense, cimicifuga foetida, scutellaria baicalensis, verbena, reed rhizome, and lophatherum gracile, is used to prepare drugs for the treatment or prevention of pharyngitis. It inhibits acute pharyngitis by improving immune cell subsets, reducing inflammatory factor levels, and mucin expression.

Benefits of technology

The Qingjin Yiqi composition significantly improves the symptoms of acute pharyngitis, increases the thymus index, reduces pharyngeal mucosal damage, regulates immune function, and reduces the levels of inflammatory factors and total mucus protein expression, providing a new approach for the safe and effective treatment of acute pharyngitis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903337A_ABST
    Figure CN118903337A_ABST
Patent Text Reader

Abstract

The invention discloses application of a Qingjin Qi-tonifying composition in preparation of a medicine for treating or preventing pharyngitis, and belongs to the technical field of traditional Chinese medicines. According to the application of the Qingjin Qi-tonifying composition in preparation of the acute pharyngitis medicine, the medical application of the Qingjin Qi-tonifying composition is expanded, and a new treatment thought is provided for treatment of pharyngitis, especially treatment of acute pharyngitis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to application of a Qingjin Yiqi composition in preparing medicines for treating or preventing pharyngitis. Background Art

[0002] Acute pharyngitis (AP) is one of the common upper respiratory tract infections in clinical practice. It is characterized by rapid onset and short course. It mainly occurs in the pharyngeal mucosa and submucosal tissue. The clinical manifestations are inflammatory reactions such as pharyngeal pain, redness and swelling of the pharyngeal mucosa, and pharyngeal sputum.

[0003] Acute pharyngitis and chronic pharyngitis are different in pathogenesis, symptoms and treatment principles. The causative factors of acute pharyngitis mainly include: infection by bacteria such as streptococci and staphylococci and various respiratory viruses. In terms of treatment, acute pharyngitis is mainly supported by non-steroidal anti-inflammatory drugs, antibiotics such as penicillin and amoxicillin, and glucocorticoids and other supportive treatments and antibacterial treatments. The purpose is to accelerate the disappearance of symptoms, shorten the infection time and prevent the occurrence of various complications. Chronic pharyngitis is a common chronic disease with a high incidence rate, repeated illness and difficult to cure. Therapeutic drugs often start from improving pharyngeal blood rheology, enhancing immunity and regulating nerve metabolism.

[0004] Although the temporary discomfort of AP is not life-threatening, if it is not treated in time, it may be prolonged and easily turn into chronic pharyngitis. Moreover, when AP occurs, excessive swelling of pharyngeal lymph nodes or mucosa and increased pharyngeal secretions can easily cause sudden conditions such as pharyngeal obstruction and dyspnea. For some people with low immunity, such as children and the elderly, it may further develop into lower respiratory tract infections such as bronchitis and pneumonia, and even lead to more serious invasive infections. Therefore, it is very important to prevent and treat AP. In clinical practice, AP treatment is mainly based on antibiotics. However, excessive use of antibiotics can lead to problems such as drug resistance and ecological flora disorder. It is of clinical significance to find specific, safe and effective AP treatment drugs.

[0005] Respiratory pathogen infection can trigger the activation of the innate and adaptive immune systems, leading to increased cytokine secretion and inflammatory response. T lymphocyte subsets are one of the main regulatory cells and effector cells of the body's immune system, which can maintain the balance of the body's immune function by recognizing and presenting antigens. Studies have shown that CD4 + T lymphocytes and CD4 + / CD8 + The ratio decreased significantly, CD8 +The proportion of T lymphocytes increased significantly. Under the stimulation of T lymphocyte subsets, the secretory function of B lymphocytes can be enhanced, further aggravating the inflammatory response. In particular, during the development of pharyngitis, mucosal immunity is also in a highly activated state: it can synthesize and secrete immunoglobulin A (IgA) through plasma cells in the submucosal lymphoid tissue, and further promote epithelial cells to secrete secretory immunoglobulin A (SIgA). SIgA plays a major role in mucosal immunity. It can inhibit the adhesion of pathogens to the mucosal surface and maintain mucosal integrity. Studies have shown that 75-85% of nasopharyngeal patients have lower mucosal SIgA levels than normal people, indicating that their respiratory mucosal immune function is low. Therefore, increasing SIgA levels has also become an important indicator for evaluating whether drugs can inhibit AP.

[0006] Literature has confirmed that the levels of inflammatory factors such as IL-6, TNF-α, and IL-1β in the serum of patients with pharyngitis are significantly increased. Animal experimental studies have found that pathological damage occurs in the pharyngeal tissue of rats with AP induced by ammonia, with a large number of inflammatory cells infiltrating, and the levels of inflammatory factors TNF-α and IL-6 are significantly increased. PGE2 is a key mediator of inflammatory response and can be synthesized by COX-2 catalytic enzyme during the metabolic conversion of arachidonic acid. It has been reported that the expression of COX-2 and the secretion of PGE2 are increased in rats with pharyngitis induced by ammonia and mice with ovalbumin-induced asthma.

[0007] Mucin is the main component of mucus, produced by airway epithelial goblet cells, and is the first barrier for pathogens to reach airway epithelial cells. Mucin is mainly divided into two types: transmembrane type and secretory type. Among them, MUC5AC is a major secretory mucin produced by airway epithelial goblet cells. Studies have shown that abnormal expression of MUC5AC is a marker for respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. In addition, reports have shown that overexpression of MUC5AC was detected in the trachea and lung tissues of asthmatic mice induced by house dust mites and COPD mice induced by live rhinovirus. Stimuli such as cytokines, EGF, elastase, and bacterial products can induce high expression of MUC5AC in NCI-292 cells.

[0008] The Qingjin Yiqi Recipe (QJYQ) contains Ginseng Radix Et Rhizoma, Ophiopogonis Radix, Schisandrae Chinensis Fructus, Poria, Pinelliae Rhizoma, Coix Semen, Scrophulariae Radix, Atractylodes Rhizoma, Citri Reticulatae Pericarpium, Glycyrrhizae Radix Et Rhizoma, Bupleuri Radix, Cimicifugae Rhizoma, Scutellariae Radix, Verbenae Herba, Phragmitis Rhizoma) and Lophatheri Herba, a total of 16 Chinese medicines, have the effects of nourishing qi and yin, clearing away heat and dampness, strengthening the spleen and harmonizing the middle, and can be used to regulate the body's immune function. Previous pharmacological studies have confirmed that Qingjin Yiqi prescription has antiviral and immunomodulatory effects, but its effect on AP and its active ingredients have not been reported. Summary of the invention

[0009] In view of this, the purpose of the present invention is to provide an application of a Qingjin Yiqi composition in the preparation of an acute pharyngitis drug, and to evaluate the effect of the Qingjin Yiqi composition in inhibiting rat AP by evaluating indicators such as apparent indicators, histopathological observation, immune cells, inflammatory factors, mucins, and MUC5AC.

[0010] To achieve the above-mentioned object of the invention, the technical solution of the present invention is as follows:

[0011] The invention provides application of a Qingjin Yiqi composition in preparing a medicine for treating or preventing pharyngitis.

[0012] Preferably, the pharyngitis is at least one of acute pharyngitis and chronic pharyngitis.

[0013] Further preferably, the pharyngitis is acute pharyngitis.

[0014] Preferably, the treatment of pharyngitis is at least one of improving body weight, increasing thymus index, reducing pharyngeal mucosal damage, improving pharyngeal and tracheal tissue pathological conditions, improving abnormal changes in immune cell subsets, improving mucosal immune function, improving pharyngeal epithelial damage, reducing inflammatory factor levels, and reducing the expression of total mucus protein and MUC5AC.

[0015] Further preferably, the treatment of pharyngitis is to simultaneously improve body weight, increase thymus index, reduce pharyngeal mucosal damage, improve pharyngeal and tracheal tissue pathological state, improve abnormal changes in immune cell subsets, improve mucosal immune function, improve pharyngeal epithelial damage, reduce the level of inflammatory factors, and reduce the expression of total mucus protein and MUC5AC.

[0016] Preferably, the improvement of the pathological state of pharyngeal and tracheal tissues is to reduce the hypervascularization, congestion and inflammatory cell infiltration under the epithelium of the pharynx and trachea, and improve the thickening of the glandular wall.

[0017] Preferably, the improvement of abnormal changes in immune cell subsets is to inhibit the decrease in the proportion of CD4+T lymphocytes and the increase in the proportion of CD8+T lymphocytes, and to inhibit the increase in WBC neutrophils.

[0018] Preferably, the reducing of inflammatory factor levels is to inhibit the increase of IL-6, IL-1β, TNF-α and PGE2 levels.

[0019] Preferably, the Qingjinyiqi composition is composed of ginseng, ophiopogon japonicus, schisandra chinensis, tuckahoe, pinellia, coix seed, scrophularia, atractylodes, tangerine peel, liquorice, bupleurum, cimicifuga, scutellaria baicalensis, verbena, reed root and lophatherum gracile.

[0020] Further preferably, the Qingjin Yiqi composition consists of 1-5 parts of ginseng, 4-8 parts of Ophiopogon japonicus, 1-5 parts of Schisandra chinensis, 5-10 parts of Poria cocos, 5-10 parts of Pinellia ternata, 8-12 parts of Coix seeds, 5-8 parts of Scrophularia ningpoensis, 2-6 parts of Atractylodes lancea, 5-8 parts of Tangerine peel, 1-5 parts of Licorice, 4-8 parts of Bupleurum chinense, 1-5 parts of Cimicifuga heracleifolia, 8-12 parts of Scutellaria baicalensis, 8-12 parts of Verbena officinalis, 12-17 parts of Phragmites australis and 1-3 parts of Lophatherum gracile.

[0021] As a specific embodiment of the present invention, the Qingjin Yiqi composition is composed of 3 parts of ginseng, 6 parts of Ophiopogon japonicus, 3 parts of Schisandra chinensis, 8 parts of Poria cocos, 8 parts of Pinellia ternata, 10 parts of Coix seeds, 6 parts of Scrophularia ningpoensis, 5 parts of Atractylodes macrocephala, 6 parts of Tangerine peel, 3 parts of Licorice, 6 parts of Bupleurum chinense, 3 parts of Cimicifuga heracleifolia, 10 parts of Scutellaria baicalensis, 10 parts of Verbena officinalis, 15 parts of Phragmites australis and 2 parts of Lophatherum gracile.

[0022] The beneficial effects of the present invention are:

[0023] The invention provides an application of the Qingjin Yiqi composition in preparing a medicine for acute pharyngitis, expands the medical application of the Qingjin Yiqi composition, and provides a new treatment idea for the treatment of pharyngitis, especially the treatment of acute pharyngitis. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 The changes in body weight of rats in each group during the administration period (n=6);

[0025] Figure 2The changes in body weight of rats in each group after administration (n=6), compared with Control, *P<0.05, **P<0.01, ***P<0.005;

[0026] Figure 3 Effects of QJYQ on thymus index in AP rats (n=6), compared with Control, *P<0.05, **P<0.01, ***P<0.005;

[0027] Figure 4 The effect of QJYQ on the apparent indexes of AP rats (n=6). In the bar graph, from left to right are Control, AP, AP+QJYQ, AP+Amoxil; compared with Control, *P<0.05, **P<0.01, ***P<0.005; compared with AP, #P<0.05, ##P<0.01, ###P<0.005;

[0028] Figure 5 Effects of QJYQ on pharyngeal lesions in AP rats (n=6), compared with Control, *P<0.05, **P<0.01, ***P<0.005;

[0029] Figure 6 Effects of QJYQ on pharyngeal mucosal injury in AP rats (n=3), compared with Control, *P<0.05, **P<0.01;

[0030] Figure 7 The effect of QJYQ on the pathological status of pharynx and trachea in AP rats;

[0031] Figure 8 Effects of QJYQ on the number of WBC and the proportion of neutrophils in peripheral blood and TLF of AP rats (n=6), compared with Control, *P<0.05, **P<0.01, ***P<0.005;

[0032] Fig. 9 Effects of QJYQ on the proportion of T lymphocyte subsets in the peripheral blood of AP rats (n=6), compared with Control, *P<0.05, **P<0.01, ***P<0.005;

[0033] Fig.10 Effects of QJYQ on serum IgA and TLF SIgA levels in AP rats (n=6), compared with Control, *P<0.05, **P<0.01, ***P<0.005;

[0034] Fig.11The effect of QJYQ on the expression of E-cadherin in pharyngeal tissue of AP rats;

[0035] Fig.12 Effects of QJYQ on the levels of inflammatory factors in the serum of AP rats (n=6), compared with Control, *P<0.05, **P<0.01, ***P<0.005;

[0036] Fig.13 The effect of QJYQ on the expression of mucin in the pharynx of AP rats;

[0037] Fig.14 Effects of Qingjin Yiqi prescription on MUC5AC levels in pharyngeal, tracheal tissues and TLF of AP rats (n=6). Compared with Control, *P<0.05, **P<0.01, ***P<0.005. DETAILED DESCRIPTION

[0038] The following non-limiting examples can enable those skilled in the art to more fully understand the present invention, but do not limit the present invention in any way. The following content is only an exemplary description of the scope of the present invention, and those skilled in the art can make various changes and modifications to the invention of the present invention based on the disclosed content, and they should also fall within the scope of the present application.

[0039] The present invention is further described below by way of specific examples. The various chemical reagents used in the examples of the present invention are obtained through conventional commercial channels unless otherwise specified. Unless otherwise specified, the contents described below are all weight contents. Unless otherwise specified, it is understood that the process is carried out at room temperature.

[0040] 1. Materials and Methods

[0041] Experimental reagents:

[0042]

[0043]

[0044] Experimental drugs:

[0045] QJYQ (Qingjin Yiqi Composition) was provided by the Modern Chinese Medicine Innovation Center of Tianjin University of Traditional Chinese Medicine, batch number SJX2020001. The formula consists of 3 parts of ginseng, 6 parts of Ophiopogon japonicus, 3 parts of Schisandra chinensis, 8 parts of Poria cocos, 8 parts of Pinellia ternata, 10 parts of Coix seeds, 6 parts of Scrophularia ningpoensis, 5 parts of Atractylodes macrocephala, 6 parts of Tangerine peel, 3 parts of Licorice, 6 parts of Bupleurum chinense, 3 parts of Cimicifuga heracleifolia, 10 parts of Scutellaria baicalensis, 10 parts of Verbena officinalis, 15 parts of Phragmites australis and 2 parts of Lophatherum gracile. The dosage for rats in the experiment was 3.4 g / kg.

[0046] Amoxicillin (Amoxil) was purchased from Shandong Zibo Xinda Pharmaceutical Co., Ltd. Batch No. 191040. The clinical equivalent dose was 0.36 g / kg.

[0047] The standard strain of Staphylococcus aureus was purchased from ATCC, catalog number 6538.

[0048] Experimental Animals:

[0049] 24 SPF male SD rats, weighing 180-220 g, were purchased from Beijing Huafukang Biotechnology Co., Ltd., with a certificate number of 110322230101674074. This experimental procedure was approved by the Animal Research Committee of Tianjin University of Traditional Chinese Medicine (TCM-LAEC2023175) and was kept in the Animal Center of Tianjin University of Traditional Chinese Medicine.

[0050] Experimental methods:

[0051] 1.1 Preparation of solutions and drugs

[0052] (1) QJYQ: Prepare before use. Weigh 6.8 g of QJYQ powder and add 20 mL of pure water to prepare a 0.34 g / mL solution.

[0053] (2) Amoxil: Prepare before use. Weigh 0.72 g of Amoxil granules and add 20 mL of pure water to prepare a 0.036 g / mL solution.

[0054] (3) LB medium: 1 g yeast extract, 2 g peptone, 2 g sodium chloride, and 200 mL double distilled water. Mix well, sterilize by high pressure, and store at 4°C until use.

[0055] 1.2 Bacterial culture

[0056] Select a colony of Staphylococcus aureus and inoculate it in LB liquid medium, shake it at 37℃ for 16h. Then centrifuge the bacterial solution for 1min, discard the supernatant, add new medium to resuspend the bacterial pellet, mix well, and adjust the bacterial solution concentration to 1.0×10 8 CFU / mL.

[0057] 1.3 Establishment of acute pharyngitis rat model and drug administration

[0058] Twenty-four rats were randomly divided into four groups, each with six rats, namely the control group (Control), acute pharyngitis group (AP), Qingjin Yiqi group (QJYQ) and positive drug group (Amoxicillin). The rats in the QJYQ group were first intragastrically administered with a dose of 3.4 g / kg for 3 days. After 3 days, except for the Control group, the rats in the remaining groups were injected with S. aureus (2×10 7CFU) for 2 consecutive days to establish the AP rat model. At the same time as the modeling, the positive drug group began to be gavaged with Amoxil at a dose of 0.36 g / kg, and the QJYQ group continued to be administered for 7 days. Weigh 1 hour after the last administration and observe the following indicators.

[0059] (1) Scoring of rats’ apparent behavioral indicators

[0060] One hour after the last administration, the behavioral characteristics of each rat were observed and scored according to the behavioral and physical scoring standards.

[0061]

[0062] (2) Evaluation of rat pharyngeal lesions

[0063] One hour after the last administration, the color, congestion and swelling of the rat's pharyngeal mucosa and saliva secretion were observed and scored according to the pathological scoring criteria.

[0064]

[0065] (3) Evans blue (EB) staining method to evaluate the integrity of pharyngeal mucosa

[0066] One hour after the last administration, three rats from the Control, AP, and QJYQ groups were randomly selected and injected with EB dye (30 mg / kg) through the tail vein for staining for 1 hour. Then the pharyngeal tissue was broken and incubated in formamide solution for 24 hours at 55°C, the supernatant was aspirated, and the absorbance at 620 nm was measured.

[0067] 1.4 Post-sampling testing indicators and methods

[0068] (1) Rat peripheral blood test

[0069] Blood was collected from the abdominal aorta of rats, and the blood was collected for detecting the number of neutrophils and leukocytes. The serum was used to determine the protein levels of inflammatory factors and was packaged and stored at -80°C.

[0070] (2) Airway lavage and cell counting in rats

[0071] After blood collection, the chest cavity was exposed, the last section of the trachea was ligated, 1 mL of PBS was injected, and the syringe was slowly withdrawn. This was repeated 3 times to obtain a lavage fluid with a recovery rate of about 80%. The TLF was centrifuged at 1000 rpm for 10 min. The cell pellet was resuspended in 100 μL PBS for neutrophil and leukocyte counting. The supernatant was aliquoted and stored at -80°C for subsequent index detection.

[0072] (3) Calculation of rat thymus index

[0073] The rats were weighed and killed, the thymus tissue was separated and taken out, the wet weight of the tissue was accurately weighed, and the thymus index was calculated according to the organ index formula: organ wet weight (g) / rat body weight (g) × 100%.

[0074] 1.5 Pathological testing

[0075] The rat pharynx and trachea were fixed in 10% neutral buffered formalin for more than 24 hours; the dehydration box was placed in a dehydrator for dehydration with graded ethanol; the paraffin-soaked tissue was placed in an embedding machine for embedding; and 5 μm thick sections were cut. The paraffin sections were dewaxed with xylene, washed with various levels of ethanol and then with water, and then stained with HE and observed under an optical microscope to evaluate the changes in tissue pathology.

[0076] 1.6 Enzyme-linked immunosorbent assay (ELISA)

[0077] Before the experiment, the serum was thawed on ice, and ELISA was used to detect the levels of immunoglobulin IgA in rat serum and SIgA in TLF; cytokines TNF-α, IL-6, IL-1β and PGE2; and the content of MUC5AC in pharyngeal, tracheal tissues and TLF.

[0078] Determination of immunoglobulin A content in serum:

[0079] (1) Prepare concentration gradients of standard solution and washing solution according to the kit instructions.

[0080] (2) Add 50 μL of the corresponding solution to each well, cover the membrane and incubate at 37°C for 30 min.

[0081] (3) Discard the liquid, spin dry, fill each well with washing solution, let it stand for 30 seconds, then discard it. Repeat 5 times.

[0082] (4) Add 50 μL of enzyme-labeled reagent to each well, cover with membrane and incubate at 37°C for 30 min, except for the blank well.

[0083] (5) The operation is the same as (3).

[0084] (6) Add 100 μL of color developer to each well and incubate at 37°C in the dark for 10 min. Add 50 μL of stop solution to each well to terminate the reaction.

[0085] (7) Measure the OD value at a wavelength of 450 nm, draw a standard curve, and calculate the sample concentration.

[0086] Determination of cytokine levels in serum:

[0087] (1) Prepare concentration gradient standard solution, biotin antigen and washing solution according to the kit instructions.

[0088] (2) Add 50 μL of the corresponding solution to each well and cover the membrane, then incubate at 37°C for 30 min.

[0089] (3) Discard the liquid, add washing solution for 30 seconds and then discard it. Repeat 5 times.

[0090] (4) Add 50 μL of HRP membrane and incubate at 37°C for 30 min.

[0091] (5) Wash the plate: Repeat step (3).

[0092] (6) Add 50 μL of chromogen A and 50 μL of chromogen B to each well, mix well, incubate at 37°C in the dark for 10 min, and add 50 μL of stop solution to each well.

[0093] (7) Measure the OD value at a wavelength of 450 nm, draw a standard curve, and calculate the sample concentration.

[0094] 1.7AB-PAS staining

[0095] The sections were placed in a 60°C thermostat for 60 minutes; the sections were placed in xylene I, II, and gradient ethanol for dewaxing; the sections were stained with Alcian blue solution for 4 minutes, washed with tap water 3 times, 2 minutes each time; the sections were placed in an oxidant for oxidation for 5 minutes. The sections were rinsed with tap water for 1 minute, and then immersed in distilled water for 2 times, 15 seconds each time; the sections were immersed in Schiff staining solution for 8 minutes, and then rinsed with water for 8 minutes; the sections were stained with hematoxylin staining solution for 1 minute, and then washed with water; the sections were differentiated with acidic differentiation solution for 2 seconds, and then washed with water; the sections were blued with Scott blue solution for 2 minutes, and then washed with water for 2 minutes; the sections were dehydrated and sealed with neutral gum, and then observed under a microscope.

[0096] 1.8 Flow cytometry

[0097] (1) Whole blood processing:

[0098] Collect whole blood: Take 100 μL of whole blood from the anticoagulant tube and transfer it to a 1.5 mL centrifuge tube.

[0099] Lysis: Add 300 μL of red blood cell lysis buffer / tube, vortex for 5 seconds, and incubate on ice for 15 minutes.

[0100] Centrifugation: 4°C, 2200 rpm, centrifuge for 10 min and discard the supernatant.

[0101] Re-lysis: add 200 μL red blood cell lysis buffer and blow evenly, centrifuge at 4°C, 2200 rpm for 10 min, and discard the supernatant.

[0102] Washing: Add 1 mL of cell buffer and blow evenly, centrifuge at 4°C, 2200 rpm for 5 min, and discard the supernatant.

[0103] (2) Antibody staining: Add antibodies PerCP-CD4 and FITC-CD8 to every 100 μL of cell suspension and incubate at 4°C in the dark for 30 min.

[0104] (3) On-line: Add 1 mL of PBS to resuspend, centrifuge briefly, and discard the supernatant. Add 500 μL of PBS to resuspend, and use flow cytometry to detect the number of T lymphocyte subsets in whole blood.

[0105] 1.9 Immunofluorescence staining

[0106] The slices were placed in a 60°C incubator for 60 minutes; the slices were dewaxed in xylene I, II, and gradient ethanol to water; after microwave heat repair, they were slowly cooled to room temperature. Washed 3 times with TBST, 5 minutes each time; covered the tissue with 5% BSA, incubated at 37°C for 30 minutes; added E-cadherin primary antibody (1:200), covered with film, and incubated at 4°C overnight; placed the wet box at room temperature for 30 minutes, added secondary antibody to cover the tissue, covered with film, incubated at 37°C for 1 hour, washed 4 times with TBST, 5 minutes each time; added anti-fluorescence attenuation mounting agent, observed under a fluorescence microscope and collected images.

[0107] 1.10 Statistical methods

[0108] The experimental data were analyzed by GraphPad Prism 8.0.1 software, and the data were expressed as mean ± standard deviation, and one-way ANOVA was used for analysis of variance.

[0109] 2. Experimental results

[0110] 2.1QJYQ improves body weight and thymus index in AP rats

[0111] like Figure 1 As shown, the body weights of the rats in the Control group, AP group, QJYQ group, and Amoxicillin group all showed a downward trend on the 5th day; and the body weights of the rats in the QJYQ group and Amoxicillin group showed an upward trend starting from the 8th day.

[0112] like Figure 2 As shown, on the 11th day, the body weight of rats in the AP group was significantly reduced compared with that in the Control group; the reduction in body weight of rats was significantly reversed after administration of QJYQ and Amoxicillin, respectively.

[0113] like Figure 3 As shown, compared with the Control group, the thymus index of rats in the AP group was also significantly decreased; the decrease in the thymus index was significantly improved after administration of QJYQ and Amoxicillin.

[0114] 2.2QJYQ improves the apparent parameters of AP rats

[0115] like Figure 4 As shown, compared with the rats in the Control group, the fur color and activity of the rats in the AP group were significantly reduced; compared with the AP group, the fur color and activity of the rats in the QJYQ group were significantly improved; the rats in the Amoxicillin group also showed similar recovery.

[0116] 2.3QJYQ alleviates pharyngeal lesions and mucosal damage in AP rats

[0117] (1) QJYQ alleviates pharyngeal lesions in AP rats

[0118] like Figure 5 The results showed that the pharyngeal mucosa of the rats in the Control group was light red, with a moist and shiny surface, no secretions, congestion, and swelling; compared with the Control group, the pharyngeal mucosa of the rats in the AP group had poor gloss, obvious tissue lesions, more mucosal secretions, and moderate congestion and swelling, indicating that the model was successful; the pharynx of the rats in the QJYQ group was accompanied by a small amount of secretions, mild congestion and swelling, but it was significantly improved compared with the rats in the AP group; the rats in the Amoxicillin group also had similar recovery conditions.

[0119] (2) QJYQ reduces pharyngeal mucosal damage in AP rats

[0120] like Figure 6 As shown in the figure, EB staining was performed in the pharyngeal tissue to quantify the extent of pharyngeal mucosal damage in rats. The extravasation of EB dye in the pharynx of rats in the Control group was minimal, and compared with the Control group, there was a large amount of extravasation of EB dye in the pharyngeal mucosa of rats in the AP group, and the staining of rats in the QJYQ group was significantly reduced after drug administration.

[0121] (3) QJYQ improves the pathological status of pharyngeal and tracheal tissues in AP rats

[0122] HE staining was used to detect the pathological state of rat pharynx and trachea. Figure 7 As shown in the figure, compared with the rats in the Control group, the pharyngeal lamina propria and submucosal blood vessels of the rats in the AP group increased and were congested, and a large number of inflammatory cells infiltrated, and the glandular wall was significantly thickened compared with the normal group; compared with the AP group, the glandular wall of the rats in the QJYQ group returned to normal levels, the degree of inflammatory cell infiltration in the mucosa and submucosa was significantly reduced, and the muscularis fibers were tightly arranged.

[0123] Compared with the rats in the Control group, tracheal lesions were also observed in the rats in the AP group. The rats in the AP group had tracheal cilia loss, inflammatory cell infiltration, and obvious submucosal epithelium, which were significantly improved after administration of QJYQ. The recovery of the rats in the Amoxil group was similar to that of the rats in the QJYQ group, and the pharyngeal and tracheal lesions were improved.

[0124] 2.4QJYQ improves the abnormal changes of immune cell subsets in AP rats.

[0125] (1) QJYQ improves abnormal changes in WBC count and neutrophil ratio in peripheral blood and TLF of AP rats

[0126] In terms of the number of immune cells, Figure 8 As shown, compared with the rats in the Control group, the number of WBC and the proportion of neutrophils in the peripheral blood of the rats in the AP group were significantly increased; compared with the rats in the AP group, QJYQ effectively inhibited the increase of the number of WBC and the proportion of neutrophils in the peripheral blood; Amoxil had a tendency to inhibit the number of WBC and the proportion of neutrophils in the peripheral blood. Compared with the rats in the Control group, the number of WBC and the proportion of neutrophils in the TLF of the rats in the AP group were significantly increased; compared with the rats in the AP group, QJYQ treatment effectively inhibited the increase of the number of WBC and the proportion of neutrophils in the TLF; Amoxil inhibited the number of WBC and the proportion of neutrophils in the TLF.

[0127] (2) QJYQ improves the abnormal changes in the proportion of T lymphocyte subsets in the peripheral blood of AP rats

[0128] like Fig. 9 The results showed that compared with the Control group, the number of CD4 + The proportion of T lymphocytes decreased significantly, and CD8 + The proportion of T lymphocytes increased significantly, and CD4 + / CD8 + Compared with the rats in the AP group, the CD4 + The proportion of T lymphocytes tended to increase, and CD8 + The proportion of T lymphocytes tended to decrease, and CD4 + / CD8 + The ratio of was significantly improved. This suggests that the function of the immune system is suppressed during AP and QJYQ has an immunomodulatory effect.

[0129] 2.5QJYQ improves mucosal immune function in AP rats

[0130] We quantified total IgA in serum and SIgA levels in TLF. Fig.10As shown in the figure, compared with the rats in the Control group, the IgA level in the serum of the rats in the AP group was significantly increased, and it was significantly decreased after QJYQ treatment. The IgA level in the serum of the rats in the Amoxicillin group showed a decreasing trend, but it was not significant. Compared with the rats in the Control group, the SIgA level in the TLF of the rats in the AP group was significantly decreased, and compared with the rats in the AP group, the SIgA level in the TLF of the rats in the QJYQ group was significantly increased. The SIgA level in the TLF of the rats in the Amoxicillin group also showed a significant increase.

[0131] 2.6QJYQ upregulates E-cadherin expression in pharyngeal and tracheal tissues of AP rats

[0132] like Fig.11 As shown, compared with the rats in the Control group, the expression of E-cadherin in the pharyngeal epithelium of the rats in the AP group was decreased, resulting in damaged epithelial barrier. Compared with the rats in the AP group, the expression of E-cadherin in the pharyngeal tissue of the rats in the QJYQ group after administration was significantly increased, indicating that QJYQ has a significant improvement effect on the pharyngeal epithelial damage in AP rats.

[0133] 2.7QJYQ reduces the levels of inflammatory factors in the serum of AP rats

[0134] like Fig.12 As shown, compared with those of the rats in the Control group, the levels of inflammatory factors IL-1β, PGE2, IL-6 and TNF-α in the serum of the rats in the AP group were significantly increased; compared with those of the rats in the AP group, the increased levels of IL-6, IL-1β, TNF-α and PGE2 in the serum of the rats in the QJYQ group were significantly inhibited after administration; the level of IL-6 in the serum of the rats in the Amoxicillin group was significantly decreased, and the levels of IL-1β, TNF-α and PGE2 showed a decreasing trend but without significance.

[0135] 2.8QJYQ reduces the expression of total mucus protein and MUC5AC in AP rats

[0136] (1)1.2.8.1QJYQ reduces the expression of mucin in pharyngeal tissue of AP rats

[0137] like Fig.13 As shown, compared with the rats in the Control group, the area of ​​total mucus protein in the submucosal glands of the rats in the AP group was significantly increased, and the expression of mucus protein in the submucosal glands of the rats in the QJYQ group was significantly reduced after administration.

[0138] (2) 1.2.8.2QJYQ reduces the expression of MUC5AC in pharyngeal, tracheal tissues and TLF in AP rats

[0139] like Fig.14As shown, compared with the rats in the Control group, the MUC5AC levels in the pharynx, trachea and TLF of the rats in the AP group were significantly increased; compared with the AP group, the increase in the MUC5AC levels in the pharynx, trachea and TLF of the rats in the QJYQ group after administration was significantly inhibited.

[0140] 3. Results and Discussion

[0141] QJYQ can significantly improve the body weight, thymus index, activity and fur color of AP rats induced by S. aureus, and reduce the amount of EB dye attached to pharyngeal tissue; pathological staining showed that QJYQ administration can significantly reduce the increase in blood vessels, congestion, and inflammatory cell infiltration in the pharyngeal and tracheal epithelium, and the thickening of the gland wall was significantly improved; the abnormal decrease of E-cadherin in pharyngeal epithelial tissue was significantly inhibited; the increase of WBC neutrophils in peripheral blood and TLF was significantly inhibited; flow cytometry showed that CD4 + Decreased proportion of T lymphocytes and CD8 + The increase in the proportion of T lymphocytes was significantly inhibited; ELISA results confirmed that QJYQ could inhibit the increase in total IgA levels and the decrease in SIgA levels, and the increase in the levels of inflammatory factors IL-1β, PGE2, TNF-α and IL-6 was also significantly inhibited; AB-PAS staining also confirmed that the area of ​​total mucus protein in the superficial epithelium of the pharynx was significantly reduced; and the MUC5AC level in the pharynx, trachea and TLF was reduced.

Claims

1. Application of the Qingjin Yiqi composition in preparing medicine for treating or preventing pharyngitis.

2. The use according to claim 1, characterized in that: The pharyngitis is at least one of acute pharyngitis and chronic pharyngitis.

3. The use according to claim 2, characterized in that: The pharyngitis is acute pharyngitis.

4. The use according to claim 1, characterized in that: The treatment of pharyngitis is at least one of improving body weight, increasing thymus index, reducing pharyngeal mucosal damage, improving pharyngeal and tracheal tissue pathological conditions, improving abnormal changes in immune cell subsets, improving mucosal immune function, improving pharyngeal epithelial damage, reducing inflammatory factor levels, and reducing the expression of total mucus protein and MUC5AC.

5. The use according to claim 4, characterized in that: The treatment of pharyngitis is to simultaneously improve body weight, increase thymus index, reduce pharyngeal mucosal damage, improve pharyngeal and tracheal tissue pathological conditions, improve abnormal changes in immune cell subsets, improve mucosal immune function, improve pharyngeal epithelial damage, reduce inflammatory factor levels, and reduce the expression of total mucus protein and MUC5AC.

6. The use according to claim 5, characterized in that: The improvement of the pathological state of pharyngeal and tracheal tissues is to reduce the increase in blood vessels, congestion and inflammatory cell infiltration under the epithelium of the pharynx and trachea, and improve the thickening of the glandular wall.

7. The use according to claim 5, characterized in that: The improvement of abnormal changes in immune cell subsets is to inhibit the decrease in the proportion of CD4+T lymphocytes and the increase in the proportion of CD8+T lymphocytes, and to inhibit the increase in WBC neutrophils.

8. The use according to claim 5, characterized in that: The reducing of the inflammatory factor level is to inhibit the increase of IL-6, IL-1β, TNF-α and PGE2 levels.

9. The use according to claim 1, characterized in that: The composition for clearing away the internal heat and replenishing the qi is composed of ginseng, ophiopogon japonicus, schisandra chinensis, tuckahoe, pinellia tuber, coix seed, scrophularia ningpoensis, atractylodes lancea, tangerine peel, liquorice, bupleurum, cimicifuga heracleifolia, scutellaria baicalensis, verbena, reed root and lophatherum gracile.

10. The use according to claim 1, characterized in that: The Qingjin Yiqi composition consists of 1-5 parts of ginseng, 4-8 parts of ophiopogon japonicus, 1-5 parts of schisandra chinensis, 5-10 parts of tuckahoe, 5-10 parts of pinellia tuber, 8-12 parts of coix seed, 5-8 parts of figwort, 2-6 parts of atractylodes, 5-8 parts of tangerine peel, 1-5 parts of liquorice, 4-8 parts of bupleurum, 1-5 parts of cimicifuga, 8-12 parts of scutellaria baicalensis, 8-12 parts of verbena, 12-17 parts of reed root and 1-3 parts of lophatherum gracile.

Citation Information

Patent Citations

  • Traditional Chinese medicine composition for infectious disease rehabilitation and application thereof

    CN113616747A

  • Application of Qingjin Qi-tonifying formula in preparation of medicine for improving airway remodeling

    CN116531472A